Clinical trial · Observational
Risk Scoring Model for Endometrial Cancer
Assessment of Risk Scoring Model for Prediction of Endometrial Cancer Among Symptomatic Postmenopausal Women(a Prospective Cohort Study).
NCT03298100CI-TRIAL-00036285CohortunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A prospective cohort study to assess RHEA ( recurrent vaginal bleeding, hypertension, endometrial thickness and age) scoring model for prediction of endometrial carcinoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oncology | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Scoring model | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Postmenopausal women
- interventionNames
- Other: Scoring model
Primary outcomes (1)
- measure
- Specificity and sensitivity of RHEA scoring mdel
- timeFrame
- One year
- description
- Positive and negative productive values, specificity and sensitivity of RHEA scoring model
Secondary outcomes (1)
- measure
- Variables to increase specificity and sensitivity of the score model
- timeFrame
- One year
- description
- Obesity, diabetes mellitus and family history
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: \- All postmenopausalwomen with vaginal bleeding and endometrial thickness more than 4 mm Exclusion Criteria: * all patients with vaginal bleeding arising from cervical or vaginal or vulval disease or due to hormonal replacement therapy (scheduled bleeding).
References
Publications (0)
Data not yet available
No reference posted for this study.